Galapagos NV is to acquire two companies with a presence in cell therapy as it takes steps to broaden its business under new leadership. The Dutch company has reached separate agreements to purchase CellPoint BV, a manufacturing company in the Netherlands, and AboundBio Inc, a US drug discovery company with an antibody library and antibody engineering capabilities.
Bpifrance, the French national investment bank, has issued a grant valued at €10 million to Osivax SAS, a biotech company based in Lyon, to advance development of a broad-spectrum influenza vaccine candidate. The financing is part of a larger initiative by the French government to promote medical innovation and prepare for future pandemics and infectious diseases. Osivax will use the funds to prepare its vaccine, OVX836, for a Phase 2b field efficacy trial against a broad range of circulating influenza strains.
Faron Pharmaceuticals Ltd of Finland has reported top-line, 12 month survival data for its antibody drug bexmarilimab showing that a significant number of patients who benefited from the treatment were still alive at 12 months. The Phase 1/2 MATINS study is investigating the safety and efficacy of bexmarilimab monotherapy in 10 different metastatic or inoperable solid tumour cohorts.
Financial Strategy
Spotting biotech opportunities
in a changing market
By Jasper Bos
Antimicrobial Review
New research, new payment models
By Peter Charlish
Research Strategy
Novel insights into ocular disease
By Rafiq Hasan
ASCO 2022
Annual meeting highlights new
cancer data - and a surprise
Clinical Strategy
Cell therapy shows promise
in pancreatic cancer
By Rob Meijer and Ilona Enninga
The Inventive Step
Interview with ImmunOs Therapeutics
